Law360, New York (August 19, 2009) -- Pharmaceutical giant Merck & Co. Inc. has asked a judge to exclude the testimony of the doctor who said his patient, the plaintiff in a bellwether case alleging harmful drug side effects, developed a degenerative bone disease from the osteoporosis drug Fosamax.
In a motion filed Tuesday in the U.S. District Court for the Southern District of New York, Merck contends that testimony from Dr. Patrick Anastasio lacks relevancy and “does nothing...
